- In October 2024, Sphere Fluidics unveiled Cyto-Mine Chroma, the second generation of its Cyto-Mine platform, offering enhanced features such as multiplexing and increased assay flexibility. This advanced platform is designed to improve the efficiency and precision of single-cell functional analysis workflows, making it a valuable tool for researchers in drug discovery and biotechnology applications.
- In September 2024, Ncardia introduced a set of ready-to-use cell-based assays designed to streamline the screening and selection of potential treatments for neurodegenerative conditions like Parkinson's disease. These assays utilize induced pluripotent stem cells (iPSCs) derived from human sources. iPSCs are capable of transforming into nearly any cell type. The process begins by obtaining cells from healthy individuals or patients and then reprogramming them into a stem-cell-like state in the laboratory
